AstraZeneca cuts Brilinta sales hopes on artery disease failure

AstraZeneca cuts Brilinta sales hopes on artery disease failure
 

AstraZeneca's (AZN.L) heart drug Brilinta has failed to help patients with serious circulatory problems in their legs, prompting the company to scrap a $3.5 billion-a-year (2.75 billion pounds) sales target for the medicine by 2023.
AstraZeneca said on Tuesday Brilinta did not show a benefit over older blood thinner clopidogrel in treating peripheral artery disease (PAD) in a large-scale clinical trial. PAD usually affects the legs.
Clopidogrel is the generic name of Sanofi's (SASY.PA) former blockbuster drug Plavix, which is now off patent.
The setback follows similar disappointing results... read more

 
4 October 2016 in Business, Views: 48
Source: Reuters
Share:
  •  





    News Widget for Webmasters



    Bring Eugene's son back home immediately

    Realtime News

     

    «
    »
    Mo Tu We Th Fr Sa Su
          1 2 3 4
    5 6 7 8 9 10 11
    12 13 14 15 16 17 18
    19 20 21 22 23 24 25
    26 27 28 29 30 31